On August 31, 3SBIO fell 5.07% in regular trading, trading at HK$16.10 per share, with turnover of approximately HK$183 million. The decline was triggered by the formal completion of a major business development transaction with Pfizer, which involved the issuance of new shares at an approximately 17% discount to market price.

Specifically, Pfizer has acquired global rights to 3SBIO's PD-1/VEGF bispecific antibody SSGJ-707 in a deal valued at over US$6 billion, with multiple Phase III clinical trials now underway globally. As part of the arrangement, 3SBIO issued discounted new shares to Pfizer, raising market concerns over near-term equity dilution. This pressure was compounded by the company's H1 results released on August 20, which showed net profit attributable to shareholders declining 15.6% year-over-year to RMB 1.147 billion, while traditional biologic product sales revenue fell 19.3%.

The broader Biotechnology sector was also under pressure, with peers including Akeso down 4.77%, Innovent Biologics down 4.84%, BeiOne Medicines down 5.17%, Everest Medicines down 5.54%, and DualityBio down 9.74%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)